IGM Biosciences Inc (IGMS)
9.40
-0.05
(-0.53%)
USD |
NASDAQ |
May 02, 10:31
IGM Biosciences Cash from Operations (TTM): -192.23M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
December 31, 2023 | -192.23M |
September 30, 2023 | -182.08M |
June 30, 2023 | -182.37M |
March 31, 2023 | -17.96M |
December 31, 2022 | -5.853M |
September 30, 2022 | -3.295M |
June 30, 2022 | 2.712M |
March 31, 2022 | -135.61M |
December 31, 2021 | -124.98M |
Date | Value |
---|---|
September 30, 2021 | -113.02M |
June 30, 2021 | -93.69M |
March 31, 2021 | -79.76M |
December 31, 2020 | -67.88M |
September 30, 2020 | -56.61M |
June 30, 2020 | -56.91M |
March 31, 2020 | -53.16M |
December 31, 2019 | -45.12M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-192.23M
Minimum
Dec 2023
2.712M
Maximum
Jun 2022
-82.81M
Average
-67.88M
Median
Dec 2020
Cash from Operations (TTM) Benchmarks
Inotiv Inc | 28.75M |
Synlogic Inc | -51.61M |
BioXcel Therapeutics Inc | -155.01M |
Xilio Therapeutics Inc | -68.62M |
NovaBay Pharmaceuticals Inc | -4.131M |